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Introduction
Medicinal plants have been used since ancient times as
medicines for the treatment of a wide range of diseases.
Morinda citrifolia L (Noni) has been used in folk reme-
dies by Polynesians for over 2000 years, and is reported
to have a broad range of therapeutic effects, including
effects against headache, fever, arthritis, gingivitis,
respiratory disorders, infections, tuberculosis and dia-
betes, it is commonly used as herbal medicines and
cosmetics.
Objectives
This study aimed to map the patent applications, analyz-
ing the potential and the evolution of technological cap-
abilities through the translated patent applications with
regard to the Morinda citrifolia.
Methods
Prospecting was carried out in the databases of the
European Patent Office (Espacenet/EP), World Intellec-
tual Property Organization (WIPO), United States
Patent and Trademark Office (USPTO) and the Insti-
tuto Nacional de Propriedade Intelectual (INPI) of the
Brazil. The keywords used was Morinda citrifolia, in
addition to the substantives skin, cosmetic, antioxidant
and dermatological. The research fields filled with the
keywords were “title” and “abstract”, and subsequently
the research was restricted application the field “inter-
national patent classification (IPC)” with the codes
A61K (regarding preparations for medical, dental or
hygiene purposes) and A61Q (regarding the specific
use of cosmetics or similar preparations for personal
hygiene).
Results
Using the keyword Morinda citrifolia, 391 patent applica-
tions were found, 9 (2.3%) in the PTO, 310 (79.28%) in the
Espacenet, 23 (5.88%) in the USPTO and 49 (12.53 %) in
the WIPO. The selection of patents was restricted combin-
ing the words skin (total of 28 applications, 24 of them
found in the Espacenet, 01 in the INPI, and 03 in the
WIPO); cosmetic (15 applications in the Espacenet), anti-
oxidant (total of 05 applications, 05 in the INPI, 01 in the
Espacent and 02 in the WIPO); and dermatological
(01 application in the Espacent). Japan and United Staes
were the main depositor countries. The highest number of
patents obtained with the combination of the keywords
Morinda, citrifolia and IPC A61K presented the subcode
A61K36, representing pharmaceutical preparations charac-
terized by active organic. Furthermore, the highest number
of patents among codes A61Q laid in the subcode A61Q1,
representing preparations for skin cleansing. The largest
number of applications occurred between 2002 and 2009.
Conclusions
The data showed that the area related to technological
research with Morinda citrifolia is promising, and that
since 2000 there has been a growing increase in the num-
ber of patents, particularly in the years 2005 and 2007.
The United States and Japan lead the ranking of deposi-
tor countries. The largest technology is involved in the
production of cosmetics for skin care, and most exploited
in the makeup production and in medicinal preparations.
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